Cowen Reaffirms “Buy” Rating for Mersana Therapeutics (NASDAQ:MRSN)

Share on StockTwits

Cowen reaffirmed their buy rating on shares of Mersana Therapeutics (NASDAQ:MRSN) in a report issued on Monday, AnalystRatings.com reports.

Several other analysts have also recently commented on the stock. ValuEngine cut shares of Mersana Therapeutics from a buy rating to a hold rating in a report on Saturday, December 21st. BidaskClub upgraded shares of Mersana Therapeutics from a buy rating to a strong-buy rating in a report on Friday, December 27th. Zacks Investment Research upgraded shares of Mersana Therapeutics from a hold rating to a buy rating and set a $6.00 price target for the company in a report on Wednesday, January 8th. Finally, HC Wainwright restated a buy rating and set a $7.00 price target on shares of Mersana Therapeutics in a report on Friday, January 10th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Mersana Therapeutics has an average rating of Hold and a consensus target price of $8.33.

MRSN stock opened at $6.16 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.12 and a current ratio of 5.12. The firm has a 50 day simple moving average of $4.75 and a 200 day simple moving average of $3.15. Mersana Therapeutics has a 52 week low of $1.32 and a 52 week high of $7.65.

Mersana Therapeutics (NASDAQ:MRSN) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.02. The business had revenue of $0.84 million during the quarter, compared to analysts’ expectations of $0.50 million. Mersana Therapeutics had a negative net margin of 79.49% and a negative return on equity of 41.14%. On average, sell-side analysts forecast that Mersana Therapeutics will post -0.59 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of MRSN. Boxer Capital LLC acquired a new stake in shares of Mersana Therapeutics during the second quarter worth approximately $8,440,000. BlackRock Inc. lifted its stake in Mersana Therapeutics by 166.2% in the second quarter. BlackRock Inc. now owns 2,390,463 shares of the company’s stock valued at $9,681,000 after acquiring an additional 1,492,618 shares during the last quarter. Vanguard Group Inc. lifted its stake in Mersana Therapeutics by 26.9% in the second quarter. Vanguard Group Inc. now owns 1,903,502 shares of the company’s stock valued at $7,709,000 after acquiring an additional 403,011 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Mersana Therapeutics in the second quarter valued at approximately $676,000. Finally, Millennium Management LLC lifted its stake in Mersana Therapeutics by 136.0% in the third quarter. Millennium Management LLC now owns 42,524 shares of the company’s stock valued at $67,000 after acquiring an additional 160,624 shares during the last quarter. Institutional investors and hedge funds own 80.37% of the company’s stock.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.

Read More: Growth Stocks

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Abbott Laboratories  Updates FY 2020
Pre-Market Earnings Guidance
Abbott Laboratories Updates FY 2020 Pre-Market Earnings Guidance
Express  Releases Q4 2019
Pre-Market Earnings Guidance
Express Releases Q4 2019 Pre-Market Earnings Guidance
MarineMax  Updates FY20 Earnings Guidance
MarineMax Updates FY20 Earnings Guidance
Squar Milner Financial Services LLC Cuts Position in Invesco BulletShares 2022 Corporate Bond ETF
Squar Milner Financial Services LLC Cuts Position in Invesco BulletShares 2022 Corporate Bond ETF
Vanguard Russell 2000  Stock Position Trimmed by Janney Montgomery Scott LLC
Vanguard Russell 2000 Stock Position Trimmed by Janney Montgomery Scott LLC
Janney Montgomery Scott LLC Has $14.72 Million Stake in L3Harris
Janney Montgomery Scott LLC Has $14.72 Million Stake in L3Harris


 
© 2006-2020 Zolmax.